

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 1 | of | 10 |

| U.S. PATENT DOCUMENTS | | | | | | |
|------------------------|--------------------------|--|---|--|---|--|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | | Number - Kind Code ² (if known) | | | | |
| KH | AA | US1974/3823135 | 07-09-1974 | Pilgram et al. | | |
| | AB | US1996/5512549 | 04-30-1996 | Chen et al. | | |
| | AC | US1996/5580979 | 12-03-1996 | Bachovchin | | |
| | AD | US1997/5614492 | 03-25-1997 | Habener | | |
| | AE | US2000/6156739 | 12-5-2000 | Griffin et al. | | |
| | AF | US2000/6166063 | 12-26-2000 | Vilhauer | | |
| | AG | US2001/6258597-B1 | 07-10-2001 | Bachovchin | | |
| | AH | US2001/0020008-A1 | 09-08-2001 | Demuth et al. | | |
| | AI | US2001/6303661-B1 | 10-16-2001 | Demuth et al. | | |
| | AJ | US2001/6319893-B1 | 11-20-2001 | Demuth et al. | | |
| | AK | US2001/0051646-A1 | 12-13-2001 | Demuth et al. | | |
| | AL | US2002/0049153-A1 | 04-25-2002 | Bridon et al. | | |
| | AM | US2002/0049164-A1 | 04-25-2002 | Demuth et al. | | |
| | AN | US2002/6380398-B2 | 04-30-2002 | Kanstrup et al. | | |
| | AO | US2002/0082427-A1 | 06-27-2002 | Demuth et al. | | |
| | AP | US2002/6448045-B1 | 09-10-2002 | Levine et al. | | |
| | AQ | US2002/0198242-A1 | 12-26-2002 | Demuth et al. | | |
| | AR | US2002/0198380-A1 | 12-26-2002 | Belzer et al. | | |
| | AS | US2002/6500804-B2 | 12-31-2002 | Demuth et al. | | |
| | AT | US2003/0008925-A1 | 01-09-2003 | Demuth et al. | | |
| | AU | US2003/6548481-B1 | 04-15-2003 | Demuth et al. | | |
| | AV | US2003/0092630-A2 | 05-15-2003 | Demuth et al. | | |
| | AW | US2003/0119750-A1 | 06-26-2003 | Demuth et al. | | |
| | AX | US2003/0130199-A1 | 07-10-2003 | von Hoersten et al. | | |
| | AY | US2003/0134802-A1 | 07-17-2003 | Demuth et al. | | |
| | AZ | US2003/0135023-A1 | 07-17-2003 | Demuth et al. | | |
| | BA | US2003/0148961-A1 | 08-07-2003 | Heiser et al. | | |
| | BB | US2003/0153509-A1 | 08-14-2003 | Bachovchin et al. | | |
| | BC | US2003/0162820-A1 | 08-28-2003 | Demuth et al. | | |
| | BD | US2003/0166578-A1 | 09-04-2003 | Arch et al. | | |
| | BE | US2003/6620910-B1 | 09-16-2003 | Calas et al. | | |
| | BF | US2003/0176357-A1 | 09-18-2003 | Pospisilik et al. | | |
| | BG | US2003/0199451-A1 | 10-23-2003 | Mogensen et al. | | |
| | BH | US2003/0199672-A1 | 10-23-2003 | Knudsen et al. | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/809,638 |
| | | | | Filing Date | March 24, 2004 |
| | | | | First Named Inventor | Jun Feng |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 10 | Attorney Docket Number | SYR-DPP-IV-5004-C3 |

| | | | | | |
|----|----|-------------------|------------|--------------------|--|
| KY | BI | US2003/0236272-A1 | 12-25-2003 | Richard David Carr | |
| | BJ | US2004/6703238-B2 | 03-09-2004 | Bachovchin | |
| | BK | US2004/0054171-A1 | 03-18-2004 | Jensen et al. | |
| | BL | US2004/0056876-A1 | 03-25-2004 | Hoffmann et al. | |
| | BM | US2004/0132732-A1 | 07-08-2004 | Han et al. | |
| | BN | US2004/0167191-A1 | 08-26-2004 | Demuth et al. | |
| | BO | US2004/0171555-A1 | 09-02-2004 | Demuth et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| KY | BP | FR 2.162.106 (English Abstract-1973) | 11-30-1972 | Amschler et al. | | |
| | BQ | WO 89/10701 | 11-16-1989 | BASF | | |
| | BR | EP 0378255-A2 | 07-18-1990 | Janssen Pharmaceutica | | |
| | BS | GB 2230527-A | 10-24-1990 | Imperial Chemical Industries Plc | | |
| | BT | WO 91/12001 | 08-22-1991 | Merck & Co., Inc. | | |
| | BU | WO 93/21162 | 01-28-1993 | Nissan Chemical Industries, Ltd. | | |
| | BV | WO 93/08259 (A2) | 04-29-1993 | New England Medical Center Hospitals, Inc. | | |
| | BW | WO 93/08259 (A3) | 04-29-1993 | New England Medical Center Hospitals, Inc. | | |
| | BX | EP 0547442-A1 | 06-23-1993 | E.R. Squibb & Sons, Inc. | | |
| | BY | WO 94/03055 | 02-17-1994 | U.S. Government, Secty. HHS | | |
| | BZ | EP 0587377-A2 | 03-16-1994 | Eli Lilly and Company | | |
| | CA | WO 95/35031 | 12-28-1995 | La Trobe University | | |
| | CB | WO 96/32384 | 10-17-1996 | Taiho Pharmaceutical Co., Ltd. | | |
| | CC | WO 96/38550 | 12-05-1996 | Dana-Farber Cancer Institute, Inc. | | |
| | CD | WO 97/40832 | 11-06-1997 | Hans-Knoll-Institut Fur Naturstoff | | |
| | CE | JP 9295977 | 11-18-1997 | Terumo Corp. | | |
| | CF | WO 98/00439 | 01-08-1998 | Trustees of Tufts College | | |
| | CG | WO 98/24780 | 06-11-1998 | Amgen Inc. | | |
| | CH | WO 99/16864 | 04-08-1999 | Point Therapeutics, Inc. | | |
| | CI | WO 99/38501 | 08-05-1999 | Trustees of Tufts University | | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | <i>A. M. Kim</i> | Date Considered | 10/19/2006 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/809,638 |
| | | | | Filing Date | March 24, 2004 |
| | | | | First Named Inventor | Jun Feng |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 3 | of | 10 | Attorney Docket Number | SYR-DPP-IV-5004-C3 |

| | | | | | | |
|----|----|-----------------|------------|---|--|--|
| | CJ | WO 99/50249 | 10-07-1999 | Du Pont Pharmaceuticals Company | | |
| KK | CK | WO 99-61431 | 12-02-1999 | Probiobrug | | |
| | CL | WO 99/67278 | 12-29-1999 | Pro-Biodrug | | |
| | CM | WO 99/67279 | 12-29-1999 | Pro-Biodrug | | |
| | CN | WO 00/07617 | 02-17-2000 | Novo Nordisk | | |
| | CO | WO 00/09666 | 02-24-2000 | U.S. Government, Secty. HHS | | |
| | CP | WO 00/15211 | 03-23-2000 | Akasis Pharmaceuticals, Inc. | | |
| | CQ | WO 00/76988-A1 | 04-11-2000 | Probiobrug | | |
| | CR | WO 00/34241 | 06-15-2000 | Novartis AG | | |
| | CS | WO 00/47219 | 08-17-2000 | Ontogeny, Inc. | | |
| | CT | WO 00/53171 | 09-14-00 | Molteni L. E. C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | | |
| | CU | WO 00/57721 | 10-05-2000 | Akasis Pharmaceuticals, Inc. | | |
| | CV | WO 01/14318-A2 | 03-01-2001 | Probiobrug | | |
| | CW | WO 01/34594-A1 | 05-17-2001 | Guilford Pharmaceuticals, Inc. | | |
| | CX | WO 01/52825-A2 | 07-26-2001 | Novartis AG | | |
| | CY | WO 01/56988-A1 | 08-09-2001 | Kirin Beer Kabushiki Kaisha | | |
| | CZ | WO 01/70729-A1 | 09-27-2001 | Sanofi-Synthelabo | | |
| | DA | WO 01/97808-A1 | 12-27-2001 | Smithkline Beecham PLC | | |
| | DB | WO 02/34242-A2 | 05-02-2002 | Probiobrug AG | | |
| | DC | WO 02/34243-A2 | 05-02-2002 | Probiobrug AG | | |
| | DD | WO 02/083109-A1 | 10-24-2002 | Ferring BV | | |
| | DE | JP 2002/338466 | 11-27-2002 | Tanabe Seiyaku Co Ltd | | |
| | DF | WO 03/002593-A2 | 01-09-2003 | Probiobrug AG | | |
| | DG | WO 03/002595-A2 | 01-09-2003 | Probiobrug AG | | |
| | DH | WO 03/002596-A2 | 01-09-2003 | Probiobrug AG | | |
| | DI | WO 03/016335-A2 | 02-27-2003 | Probiobrug AG | | |
| | DJ | WO 03/022871-A2 | 03-20-2003 | Probiobrug AG | | |
| | DK | WO 03/026652-A1 | 04-03-2003 | Bristol-Myers Squibb Company | | |
| | DL | WO 03/030946-A1 | 04-17-2003 | Novartis AG | | |
| | DM | WO 03/033524-A2 | 04-24-2003 | Probiobrug AG | | |
| | DN | JP 2003/128551 | 05-08-2003 | Sankyo Co LTD | | |
| | DO | WO 03/040174-A2 | 05-15-2003 | Probiobrug AG | | |
| | DP | WO 03/045228-A2 | 06-05-2003 | Trustees of Tufts College | | |
| | DQ | WO 03/045977-A2 | 06-05-2003 | Trustees of Tufts College | | |
| | DR | WO 03/048081-A2 | 06-12-2003 | Bristol-Myers Squibb Company | | |
| | DS | WO 03/048158-A1 | 06-12-2003 | Bristol-Myers Squibb Company | | |
| | DT | WO 03/057200-A2 | 07-17-2003 | Novo Nordisk | | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered/ whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/809,638 |
| | | | | Filing Date | March 24, 2004 |
| | | | | First Named Inventor | Jun Feng |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 4 | of | 10 | Attorney Docket Number | SYR-DPP-IV-5004-C3 |

| | | | | | | |
|----|----|-------------------|------------|--------------------------------|--|--|
| KH | DU | WO 03/063903-A2 | 08-07-2003 | Probiobrug AG | | |
| | DV | WO 03/072556-A1 | 09-04-2003 | Probiobrug AG | | |
| | DW | WO 03/082898-A2 | 10-09-2003 | Probiobrug AG | | |
| | DX | WO 03/092605-A2 | 11-13-2003 | Trustees of Tufts College | | |
| | DY | WO 03/099279-A1 | 12-04-2003 | Novartis AG | | |
| | DZ | WO 03/099818-A1 | 12-04-2003 | Chiron Corporation | | |
| | EA | WO 03/106416-A2 | 12-24-2003 | Smithkline Beecham Corporation | | |
| | EB | WO 2004/017989-A1 | 03-04-2004 | Probiobrug AG | | |
| | EC | JP 2004/99600-A | 04-02-2004 | Sankyo Co. Ltd. | | |
| | ED | WO 2004/031374-A2 | 04-15-2004 | Probiobrug AG | | |
| | EE | JP 2004/123738-A | 04-22-2004 | Takeda Chem Ind Ltd | | |
| | EF | WO 2004/037176-A2 | 05-06-2004 | Bristol-Myers Squibb Company | | |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| KH | EG | ARGAUD, DORIANE et al., Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993). | |
| | EH | ASHCROFT, STEPHEN J.H. et al., Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1986), 89 pp. 469-472. | |
| | EI | BAL, GUNTHER, Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors, (2002) Universiteit Antwerpen. | |
| | EJ | BARAKAT, S.E.S., Synthesis and hypoglycemic activity of some new 3-[4-[[[(cyclohexylamino) carbonyl] amino]sulfonyl]phenyl]-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000), pp. 48-57. | |
| | EK | BARAKAT, S.E.S., Synthesis and Hypoglycemic Activity of Some New 4(3H)-Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 8, No.4 (2000) pp.195-204. | |
| | EL | BAKER, B.R. et al., Irreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolic Reductase (1,2), Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48. | |
| | EM | BELGODERE, ELENA et al., Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9. | |
| | EN | BEZUGLYI, P.O. et al., Synthesis of arylsulfonyl hydrazide of 3-R-quinazolinone-4-carbonyl-2-acid, Pharmaceutical Journal (1979), pp. 70-71. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 5 | of | 10 |

| | | |
|----|----|--|
| KH | EO | BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazoline (Centipiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414. |
| | EP | BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 399-405. |
| | EQ | BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity in Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391. |
| | ER | BUCKLEY, DI, Analysis of the Degradation of Insulintropin (GLP-1 (7-37)) In Human Plasma and Production of Degradation Resistant Analogs. |
| | ES | CHATTERJEE, A.K. et al., Effect of Centipiperalone in Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008. |
| | ET | CHATTERJEE, A.K. et al., Effect of Centipiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1981) pp.270-272. |
| | EU | COPPOLA, GARY M. et al., 1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors, Bioorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558. |
| | EV | DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 <i>in Vitro</i> Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite <i>in Vivo</i> , Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957. |
| | EW | DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, Vol. 44 (1996), pp. 1125-1131. |
| | EX | DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism in Vivo, Regulatory Peptides Vol. 64 Issues 1-3 (1996) p.30. |
| | EY | DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig, Diabetes, Vol. 47 (1998), pp. 764-769. |
| | EZ | DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4. |
| | FA | DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metaformin effects on depeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 296 (2002) pp. 229-232. |
| | FB | ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, Proc. Nat. Acad. Sci. Early Edition (2003), pp. 1-6. |
| | FC | FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and In Vivo, J. Clinical Endocrinology & Metabolism (1986), pp. 898-905. |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 6 | of | 10 |

| | | | |
|----|----|---|--|
| KH | FD | GARRATT, PETER J. et al., A Novel Synthesis of Dihydropyrimidines, J. Chem. Soc., Chem. Commun. (1987), pp.568-569. | |
| | FE | GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Hydroxypyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, J. Org. Chem. (1988), pp. 1062-1069. | |
| | FF | GAZIT, AVIV et al., Tyrophostins IV - Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4- Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No.8 (1996) pp. 1203-1207. | |
| | FG | GUERRIERI, N., et al., Vanadium Inhibition of Serine and Cysteine Proteases, Comparative Biochemistry and Physiology Part A 122 (1997), pp.331-336. | |
| | FH | GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Trifazepino- and Trifazoclonquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395. | |
| | FI | GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, Nature, Vol. 223 (1969), p. 524. | |
| | FJ | GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene 5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido [1,2-a] pyrimidines, Indian Journal of Chemistry, Vol. 9 (1971), pp. 201-206. | |
| | FK | HERMECZ, ISTVAN et al., Pyrdo[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, Medicinal Research Reviews, Vol. 8, No. 2 (1988) pp.203-230. | |
| | FL | HINKE, SIMON A. et al., Metaformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochemical and Biophysical Research Communications, 291 (2002) pp. 1302-1308. | |
| | FM | HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metaformin and Dipeptidyl Peptidase IV Inhibitors, Diabetes Care, Vol. 25, No. 8 (2002) pp. 1490-1492. | |
| | FN | HOLZ, GEORGE G. et al, Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulintropic Hormone Glucagon-Like Peptide-1(7-37), Nature, Vol. 361 (1993), pp. 362-365. | |
| | FO | KHALID, NORAINI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32, Applied and Environmental Microbiology (1990), pp. 381-388. | |
| | FP | KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependant Insulintropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV, Endocrinology, Vol. 136, No. 8 (1995) 3585-3596. | |
| | FQ | KIMURA, TOSHIKIRO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, Biological & Pharmaceutical Bulletin, Vol. 19, No. 6 (1996), 897-900. | |
| ✓ | FR | KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From <i>Prevotella loescheii</i> ATCC 15930, Archives of Oral Biology, 46 (2001), 759-766. | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 7 | of | 10 |

| | | | |
|----|----|--|--|
| KH | FS | KUSAR, MIHAEL et al., Diethyl N,N-Dimethylaminomethylenemalonate in the Synthesis of Fused Heterocyclic Systems, Heterocyclic Chem. 33 (1996) pp. 1041-1046. | |
| / | FT | LI JINPING, et al., Permolybdate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, Biochemistry, 34 (1995) 6218-6225. | |
| / | FU | LIN, JIAN, Total Synthesis and Biological Evaluation of Fluoroolefin-containing Dipeptidyl Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1998). | |
| / | FV | LOESER, ERIC et al., Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, Synthetic Communications, 32(3) (2002) pp. 403-409. | |
| / | FW | MANNUCCI, EDUARDO, et al., Effect of Metformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects, Diabetes Care, Vol. 24, No. 3 (2001) 489-494. | |
| / | FX | MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum, Eur. J. Biochem, Vol. 214, 829-835 (1991). | |
| / | FY | MEYEROVITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, The Journal of Biological Chemistry, Vol. 262, No. 14 (1987) 6658-6662. | |
| / | FZ | MALLOY, J. ARDILL et al., Effect of Metformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, Diabetologia, Vol. 19 (1980) 93-96. | |
| / | GA | MUKERJEE, S.S. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm, Biochemical Pharmacology, Vol. 23 (1974) 3066-3067. | |
| / | GB | MUKERJEE, S.S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, Acta Diabet. Lat 13, 8 (1976) p 8. | |
| / | GC | MUKERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centipiperalone in Rats & Rhesus Monkeys, Indian Journal of Experimental Biology, Vol. 17 (1979) pp. 1346-1349. | |
| / | GD | MUKERJEE, S.S. et al., Tissue Distribution of [³ H]Centipiperalone after Oral Administration, Indian J. Biochem. Biophys., Vol. 17 (1980) pp. 399-401. | |
| / | GE | MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, Biochemical Pharmacology, Vol. 22 (1972) pp. 1529-1531. | |
| / | GF | MUKHERJEE, SURATH K. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats, Biochemical Pharmacology, Vol. 22 (1973) pp. 2205-2206. | |
| ✓ | GG | MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, Ind. J. Physiol. & Allied Sci., Vol. 30, No. 3 (1976) pp. 105-118. | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 8 | of | 10 |

| | | | |
|----|----|---|--|
| KY | GH | MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycaemic Agent A-4166 in Relation to Food, Diabetologia Vol. 38 A194 Supplement 1 (1995). | |
| | GI | MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centipernalone-Induced Hypoglycemia, Acta Diabet. Lat. 13, 8, (1976) pp. 8-19. | |
| | GJ | MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V - Synthesis & Hypoglycemic Activity of Some New 1-[[p-(4-OXO-2-Methyl/Phenyl-3 (4H)-Quinazolyl) Phenyl]] 3-Aryl-2-Ureas, Indian Drugs, 25 (1) (1987) pp. 19-22. | |
| | GK | MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[[p-(4-OXO-2-Substituted-3(4H)-Quinazolyl)-Phenyl] Sulphonyl]-3-Aryl/Cyclohexyl-2-Thioureas, Current Science, Vol. 56, No. 24 (1987) pp. 1263-1265. | |
| | GL | NAKAMURA, SEIJI, et al., Effect of Chronic Vanadate Administration in Partially Depancreatized Rats, Diabetes Research and Clinical Practice 27 (1995) pp. 51-59. (Abstract Only) | |
| | GM | OHKUBO, I., et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, J. Biochem. (Tokyo) (1994) 116(5) pp. 1182-11826. | |
| | GN | PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, Pharmacological Research Communications, Vol. 17, No.8 (1985) pp. 699-709. | |
| | GO | PAULY, R.P. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) in Rat Results in Improved Glucose Tolerance, Regulatory Peptides Vol. 64, Issues 1-3 (1996) p. 148. | |
| | GP | PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolid, Diabetes, Vol. 47 (1998) pp.1253-1258. | |
| | GQ | PILLAI, SREEKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, The Journal of Biological Chemistry, Vol. 260, No. 14 (1985) pp. 8384-9. | |
| | GR | PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62. Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, J. Org. Chem. 51 (1985) 394-399. | |
| | GS | POJE, M. et al., Diabetogenic action of allozan-like derivatives of uric acid, Experientia 36 (1980) pp. 78-9. | |
| | GT | POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of 5-Imino-2,4,6-(1H,3H,5H)-pyrimidinetrione Salts and Their Alloxan-like Covalent Adducts, J. Med. Chem. 26 (1983) 881-4. | |
| | GU | POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, Arzneim.-Forsch./ Drug Res. 28 (1978), 791-93. | |
| | GV | PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide1(7-36)amide in Dogs and is Degraded More Quickly in Vitro by Dog Plasma, European Journal of Drug Metabolism and Pharmacokinetics, Vol. 21 (1995), pp. 51-59. | |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Amy M</i> | Date Considered | 10/19/2006 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun Feng |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | SYR-DPP-IV-5004-C3 |
| Sheet | 9 | of | 10 |

| | | | |
|----|----|---|--|
| KH | GW | RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Suitably Functionalized 3H-quinazolin-4-ones, Bioorganic & Medicinal Chemistry 11 (2003), pp. 2439-2444. | |
| | GX | SAWYER, JAMES H. et al., Pyrido[1,2-a]pyrimidinium Salts. Part 1. Synthesis from 2- Aminopyridines and Interconversion with 2-(2-Acylvinylamino) pyridines, J.C.S. Perkin I (1972), 1138-1143. | |
| | GY | SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, Indian Journal of Experimental Biology, Vol. 34 (1996), pp. 351-355. | |
| | GZ | SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 1550 (2001), pp. 107-116. | |
| | HA | SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazino-activity of 6-polymethylenepyrimidines, Eur. J. Med. Chem. (1982), 75-79. | |
| | HB | SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, Bioorganic & Medicinal Chemistry Letters 12 (2002) pp. 2825-2828. | |
| | HC | SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolones, Indian Journal of Chemistry, Vol. 14B (1975), 536-540. | |
| | HD | SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, J. Enzyme Inhibition, Vol. 14 (1999) pp. 259-275. | |
| | HE | SHISHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion in Vitro and in Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozocin-Induced Rats, Diabetes, Vol. 41 (1992), pp. 982-988. | |
| | HF | SINYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, pp 168-171 (1986), pp. 103-105. | |
| | HG | SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, Journal of Clinical Investigation, Vol. 46, No.5 (1967) pp. 778-785. | |
| | HH | SRIVASTAVA, P.P. et al., Efficacy of Centpiperalone in Combination With Biguanide & Sulfonylurea, Indian Journal of Experimental Biology, Vol. 21 (1983), pp. 390-392. | |
| | HI | TANAKA, KEIJI et al, Vanadate Inhibits the ATP-Dependant Degradation of Proteins in Reticulocytes Without Affecting Ubiquitin Conjugation, The Journal of Biological Chemistry, Vol. 259, No. 4 (1983), 2803-2809. | |
| | HJ | VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, Annual Reports in Chemistry 36 (2001), 191-200. | |
| ✓ | HK | VILLHAUER, EDWIN B. et al., 1-[[[3-Hydroxy-1-adamantyl]amino]acetyl]-2-cyano-(5)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, J. Med. Chem. 46 (2003), pp. 2774-2789. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/809,638 |
| | | | | Filing Date | March 24, 2004 |
| | | | | First Named Inventor | Jun Feng |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 10 | of | 10 | Attorney Docket Number | SYR-DPP-IV-5004-C3 |


| | | | |
|----|----|--|--|
| KL | HL | WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2689-94. | |
| | HM | WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes, Current Opinion in Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420. | |
| | HN | YASUDA, NOBUYUKI et al. Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784. | |
| | HO | YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rats, Diabetes Research and Clinical Practice 43 (1999), pp. 9-19. | |
| | HP | ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725. | |
| | HQ | ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-56. | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

| | |
|------------------------|--------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | SYR-DPP-IV-5004-C3 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|--|---|--|---|
| | | Number - Kind Code ² (if known) | | | |
| KY | AA | US1998/5798344 | 12-25-1998 | Kuroki et al. | |
| | AB | US2002/0169159 | 11-14-2002 | Medina et al. | |
| | AC | US2003/0089234 | 4-10-2003 | Medina et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| KH | AD | BR 699812 | 11-29-1950 | The Distillers Company Limited | | |
| | AE | 53005180 A | 01-18-1978 | Sumitomo Chem | | |
| | AF | EP 1136482 A1 | 09-26-2001 | Sanofi-Synthelabo | | |
| | AG | WO 01/96295 A2 | 12-20-2001 | Novartis AG | | |
| | AH | WO 02/02560 A2 | 01-10-2002 | Novo Nordisk | | |
| | AI | WO 03/000181 A2 | 01-03-2003 | Merck & Co., Inc. | | |
| | AJ | WO 03/007888 A2 | 01-30-2003 | Adipogenix, Inc. | | |
| | AK | WO 03/027080 A1 | 04-03-2003 | Mitsubishi Pharma | | |
| | AL | WO 03/037888 A1 | 05-08-2003 | Mitsubishi Pharma | | |
| | AM | WO 03/076418 A1 | 09-18-2003 | X-Ceptor Therapeutics, Inc. | | |
| | AN | WO 04/062613 A2 | 07-29-2004 | Bristol-Myers Squibb | | |
| | AO | WO 04/085408 A1 | 10-07-2004 | Mitsubishi Pharma | | |


Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

| | |
|------------------------|--------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | SYR-DPP-IV-5004-C3 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|--|----------------|
| FK | AP | DEY, PARAMITA D., et al., Regioselective [4+2] Cycloaddition versus Nucleophilic Reactions of N-Arylamino Substituted 1,3-Diaza-1,3-Butadienes with Ketenes: Synthesis of Pyrimidinone and Fused Pyrimidine Derivatives. Part II. Tetrahedron, Vol. 53, No. 40, pp. 13829-13840, 1997. | |
| | AQ | JAKUBKIENE, VIRGINIA, et al., (G-Methyl-2methylsulfanyl-4-oxo-3,4-dihydro-3-pyrimidinyl)acetic acid and related compounds exhibiting anti-inflammatory activity. Pharmazie 57 (2002) 9, pp. 610-613. | |
| | AR | JONES, TERENCE R., et al., Azafluorenes Containing Two Bridgehead Nitrogen Atoms. Journal of the Chemical Society, Perkin Transactions 1, No. 12, December 1987, pp. 2585-2592. | |
| | AS | SHARMA, ARUN K., et al., Tandem sigmatropic shifts in [4 + 2] cycloaddition reactions of 1,3-diazabuta-1,3-dienes with butadienylketene: synthesis of pyrimidinone derivatives. J. Chem. Soc., Perkin Trans. 1, 2002, 774-784. | |
| | AT | Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310120. Beilstein Registry Number 638238 & Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1, 1968, page 92. | |
| | AU | Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310119. Beilstein Registry Number 649497 & J. Pharm. Sci. Vol. 80, No. 7, 1991, pp. 705-706. | |
| | AV | Database CA Online Chemical Abstracts Service, Columbus, OH, US; Troschuetz, Reinhard et al., The reaction of O-functional benzylmalononitriles with N-bisnucleophiles as well as alcoholates. XP-002311761 retrieved from STN Database accession No. 1994:217538 abstract & Archiv Der Pharmazie (Winheim, Germany), 326(11), 865-9 Coden: ARPMA5; ISSN: 0365-6233, 1993. | |
| | AW | Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310121. Beilstein Registry Number 7289032 & Nucleosides Nucleotides, Vol. 14, No. 3-5, 1995, pp. 653-656. | |
| | AX | Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310118. Beilstein Registry Number 7643826 & KHIM. Geterotsikl. Soedin., Vol. 32, No. 5, 1996, pp. 703-707. | |
| | AY | Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310117. Beilstein Registry Number 8373244 & KHIM. Geterotsikl. Soedin., No. 8, 1998, pp. 1125-1129. | |


Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------|------------------------|--------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/809,638 | | |
| | | Filing Date | March 24, 2004 | | |
| | | First Named Inventor | Jun FENG | | |
| | | Group Art Unit | 1614 | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | SYR-DPP-IV-5004-C3 |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|---|---|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|--|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| KH | AA | WO 03/035057 A | 05/01/2003 | Ferring B.V. | | |
| J | AB | DE 21 50 686 A1 | 4/19/1973 | Badische Anilin & Soda Fabrik AG | | |
| J | AC | EP 0 442 473 A | 08/21/1991 | Takeda Chemical Industries, Ltd. | | |


| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| KH | AD | WEBER, A.E.: Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes, Journal of Medicinal Chemistry, vol. 47, 2004 pages 4135-4141, XP002329845 | |
| J | AE | Patent Abstracts of Japan, vol. 2003, no. 12, Xanthine Derivative, December 5, 2003 & JP 2003 300977 A (Sumitomo Pharmaceut Co Ltd), October 21, 2003, Abstract | |
| J | AF | BOTTA, M., SALADINO, R., LAMBA, D. NICOLETTI, R.: Researches on Antiviral Agents. 31. Synthesis and Transformations of Racemic and Chiral 6-Oxiranyl Pyrimidinones, Tetrahedron, vol. 49, 1993, pages 6053-6070, XP002329846 | |
| J | AG | FRAISSE, L., et al. Long-Chained Substituted Uric Acid and 5,6-Diaminouracil Derivatives as Novel Agents against Free Radical Processes: Synthesis and in Vitro Activity, Journal of Medicinal Chemistry, vol. 36, 1993, pages 1456-1473, XP002329847 | |
| J | AH | KIM, H.O. et al., Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A ₃ Adenosine Receptors, Journal of Medicinal Chemistry, vol. 37, 1994, pages 3373-3382, XP002329848 | |

| | | | |
|-----------------------|--|--------------------|------------|
| Examiner Signature | | Date Considered | 10/19/2006 |
|-----------------------|--|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 14

Complete if Known

| | |
|------------------------|---------------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 1624 |
| Examiner Name | Not Yet Assigned K. Nable |
| Attorney Docket Number | DPP-IV-5004-C3 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. 1 | Document Number | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|---------------|---------------------------------|---|--|---|
| | | Number - Kind Code 2 (if known) | | | |
| KM | AA | US 3,960,949 | 6/1/1978 | Ahrens, Hanns et al. | |
| | AB | US 4,494,978 | 1/22/1985 | Chan, David C. K.; | |
| | AC | US 4,935,493 | 6/19/1990 | Bachovchin, William W. et al. | |
| | AD | US 5,366,862 | 11/22/1994 | Venton, Duane L. et al. | |
| | AE | US 5,387,512 | 02/07/1995 | Balani, Suresh K. et al. | |
| | AF | US 5,433,955 | 7/18/1995 | Bredehorst, Reinhard et al. | |
| | AG | US 5,462,928 | 10/31/1995 | Bachovchin, William W. et al. | |
| | AH | US 5,543,396 | 8/6/1996 | Powers, James C. et al. | |
| | AI | US 5,601,986 | 2/11/1997 | Takacs, Laszlo | |
| | AJ | US 5,614,379 | 3/25/1997 | MacKellar, Warren C. | |
| | AK | US 5,624,894 | 4/29/1997 | Bodor, Nicholas S. | |
| | AL | US 5,811,278 | 09/22/1998 | Okamura, Hideki et al. | |
| | AM | US 5,811,281 | 09/22/1998 | Quaroni, Andrea et al. | |
| | AN | US 5,814,460 | 9/29/1998 | Venton, Duane L. et al. | |
| | AO | US 5,885,997 | 3/23/1999 | Lohray, Vidya Bhushan et al. | |
| | AP | US 5,939,560 | 8/17/1999 | Jenkins, Paul D. et al. | |
| | AQ | US 5,965,532 | 10/12/1999 | Bachovchin, William W. | |
| | AR | US 5,985,884 | 11/16/1999 | Lohray, Vidya Bhushan et al. | |
| | AS | US 6,006,753 | 12/28/1999 | Elendic, Suad | |
| | AT | US 6,011,155 | 1/4/2000 | Villhauer, Edwin Bernard | |
| | AU | US 6,090,786 | 7/18/2000 | Augustyns, Koen Jan Ludovicus et al. | |
| | AV | US 6,107,317 | 8/22/2000 | Villhauer, Edwin Bernard | |
| | AW | US 6,110,949 | 8/29/2000 | Villhauer, Edwin Bernard | |
| | AX | US 6,124,305 | 9/26/2000 | Villhauer, Edwin Bernard | |
| | AY | US 6,129,911 | 10/10/2000 | Faris, Ronald A. | |
| | AZ | US 2001/0018210 | 8/30/2001 | Bachovchin, William et al. | |
| | BA | US 2001/0031780 | 10/18/2001 | Kanstrup, Anders et al. | |
| | BB | US 2001/0047078 | 11/29/2001 | Chang, Yie-Hwa | |
| | BC | US 6,172,081 | 1/9/2001 | Damon, Robert | |
| | BD | US 6,184,020 | 2/6/2001 | Blinkovsky, Alexander et al. | |
| | BE | US 6,201,132 | 3/13/2001 | Jenkins, Paul D. et al. | |
| | BF | US 6,214,340 | 4/10/2001 | Takeuchi, Tomio et al. | |
| | BG | US 6,235,493 | 5/22/2001 | Bissell, Eugene R. et al. | |
| | BH | US 6,251,391 | 6/26/2001 | Wilkinson, Randall Eugene et al. | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **14****Complete if Known**

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | |
|----|-----------------|------------|----------------------------------|--|
| BI | US 6,261,794 | 7/17/2001 | Chang, Yie-Hwa | |
| BJ | US 6,265,551 | 7/24/2001 | Duke-Cohan, Jonathan S. et al. | |
| BK | US 6,309,868 | 10/30/2001 | Monod, Michel | |
| BL | US 6,310,069 | 10/30/2001 | Lohray, Vidya Bhushan et al. | |
| BM | US 6,325,989 | 12/4/2001 | Duke-Cohan, Jonathan S. et al. | |
| BN | US 2002/0006899 | 1/17/2002 | Pospisilik, Andrew J. et al. | |
| BO | US 2002/0019411 | 2/14/2002 | Robl, Jeffrey A. et al. | |
| BP | US 2002/0037829 | 3/28/2002 | Aronson, Peter S. et al. | |
| BQ | US 2002/0041871 | 4/11/2002 | Brudnak, Mark A. | |
| BR | US 2002/0061839 | 5/23/2002 | Scharpe, Simon Lodewijk et al. | |
| BS | US 2002/0071838 | 6/13/2002 | Demuth, Hans-Ulrich et al. | |
| BT | US 2002/0077340 | 06/20/2002 | Sulsky, Richard et al. | |
| BU | US 2002/0082292 | 6/27/2002 | Sahoo, Soumya P. et al. | |
| BV | US 2002/0103242 | 8/1/2002 | Sahoo, Soumya P. et al. | |
| BW | US 2002/0103384 | 8/1/2002 | Kanstrup, Anders et al. | |
| BX | US 2002/0110560 | 8/15/2002 | Demuth, Hans-Ulrich et al. | |
| BY | US 2002/0115843 | 08/22/2002 | Oi, Steve et al. | |
| BZ | US 2002/0132979 | 9/19/2002 | Chen, Wen-Tien | |
| CA | US 2002/0147130 | 10/10/2002 | Huber, Brigitte T. et al. | |
| CB | US 2002/0147157 | 10/10/2002 | Connor, Gregory S. | |
| CC | US 2002/0155565 | 10/24/2002 | Garin-Chesa, Pilar et al. | |
| CD | US 2002/016100 | 02/07/2002 | Okabe, Toshiaki et al. | |
| CE | US 2002/0164759 | 11/7/2002 | Travis, James et al. | |
| CF | US 2002/0165164 | 11/7/2002 | Demuth, Hans-Ulrich et al. | |
| CG | US 2002/0183367 | 12/5/2002 | Sulsky, Richard B. et al. | |
| CH | US 2002/0193390 | 12/19/2002 | Vilhauer, Edwin Bernard | |
| CI | US 2002/0198205 | 12/26/2002 | Himmelsbach, Frank et al. | |
| CJ | US 6,335,429 | 1/1/2002 | Cal, Sui Xiong et al. | |
| CK | US 6,337,069 | 1/8/2002 | Grouzmann, Eric et al. | |
| CL | US 6,342,611 | 1/29/2002 | Weber, Eckard et al. | |
| CM | US 6,355,614 | 3/12/2002 | Wallner, Barbara P | |
| CN | US 6,395,767 | 5/28/2002 | Robl, Jeffrey A. et al. | |
| CO | US 6,432,969 | 8/13/2002 | Vilhauer, Edwin Bernard | |
| CP | US 6,447,772 | 9/10/2002 | Houston, Devin B. | |
| CQ | US 6,458,924 | 10/1/2002 | Knudsen, Liselotte Bjerre et al. | |
| CR | US 6,485,955 | 11/26/2002 | Huber, Brigitte T. et al. | |
| CS | US 6,495,544 | 12/17/2002 | Hansen, Jr., Donald W. et al. | |
| CT | US 2003/0008905 | 1/9/2003 | Demuth, Hans-Ulrich et al. | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **14****Complete if Known**

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | |
|-------------------------------------|----|-----------------|------------|------------------------------------|--|
| <input checked="" type="checkbox"/> | CU | US 2003/0027282 | 2/6/2003 | Huber, Brigitte T. et al. | |
| <input checked="" type="checkbox"/> | CV | US 2003/0040478 | 2/27/2003 | Drucker, Daniel J. et al. | |
| <input checked="" type="checkbox"/> | CW | US 2003/0045464 | 3/6/2003 | Hermeling, Ronald Norbert et al. | |
| <input checked="" type="checkbox"/> | CX | US 2003/0055052 | 3/20/2003 | Peters, Stefan et al. | |
| <input checked="" type="checkbox"/> | CY | US 2003/0060412 | 3/27/2003 | Prouty, Walter Francis et al. | |
| <input checked="" type="checkbox"/> | CZ | US 2003/0060434 | 3/27/2003 | Nielsen, Loretta et al. | |
| <input checked="" type="checkbox"/> | DA | US 2003/0087935 | 5/8/2003 | Cheng, Peter T. et al. | |
| <input checked="" type="checkbox"/> | DB | US 2003/0087950 | 5/8/2003 | DeNanteuil, Guillaume et al. | |
| <input checked="" type="checkbox"/> | DC | US 2003/0089935 | 5/15/2003 | Fan, Tso-Hung et al. | |
| <input checked="" type="checkbox"/> | DD | US 2003/0092697 | 5/15/2003 | Cheng, Peter T. et al. | |
| <input checked="" type="checkbox"/> | DE | US 2003/0096846 | 5/22/2003 | Cheng, Peter T. et al. | |
| <input checked="" type="checkbox"/> | DF | US 2003/0096857 | 5/22/2003 | Evans, David Michael et al. | |
| <input checked="" type="checkbox"/> | DG | US 2003/0100563 | 5/29/2003 | Edmondson, Scott D. et al. | |
| <input checked="" type="checkbox"/> | DH | US 2003/0103968 | 6/5/2003 | Amelsberg, Andree et al. | |
| <input checked="" type="checkbox"/> | DI | US 2003/0105077 | 6/5/2003 | Kanstrup, Anders Bendtz et al. | |
| <input checked="" type="checkbox"/> | DJ | US 2003/0119736 | 6/26/2003 | Demuth, Hans-Ulrich et al. | |
| <input checked="" type="checkbox"/> | DK | US 2003/0119738 | 6/26/2003 | Niestroj, Andre et al. | |
| <input checked="" type="checkbox"/> | DL | US 2003/0125304 | 7/3/2003 | Demuth, Hans-Ulrich et al. | |
| <input checked="" type="checkbox"/> | DM | US 2003/0130281 | 7/10/2003 | Boehringer, Markus et al. | |
| <input checked="" type="checkbox"/> | DN | US 2003/0130306 | 7/10/2003 | Devasthale, Pratik et al. | |
| <input checked="" type="checkbox"/> | DO | US 2003/0139429 | 7/24/2003 | Cohen, David Saul et al. | |
| <input checked="" type="checkbox"/> | DP | US 2003/0139434 | 7/24/2003 | Balkan, Bork et al. | |
| <input checked="" type="checkbox"/> | DQ | US 2003/0144206 | 7/31/2003 | Knudsen, Lotte Bjerre et al. | |
| <input checked="" type="checkbox"/> | DR | US 2003/0149071 | 8/7/2003 | Gobbi, Luca Claudio et al. | |
| <input checked="" type="checkbox"/> | DS | US 2003/0166662 | 9/4/2003 | Fryburg, David Albert et al. | |
| <input checked="" type="checkbox"/> | DT | US 2003/0166690 | 9/4/2003 | Ebdrup, Soren et al. | |
| <input checked="" type="checkbox"/> | DU | US 2003/0171358 | 9/11/2003 | Jeppesen, Lone et al. | |
| <input checked="" type="checkbox"/> | DV | US 2003/0171411 | 9/11/2003 | Kodra, Janos Tibor et al. | |
| <input checked="" type="checkbox"/> | DW | US 2003/0181497 | 9/25/2003 | Chen, Ping et al. | |
| <input checked="" type="checkbox"/> | DX | US 2003/0186963 | 10/2/2003 | Dorwald, Florencio Zaragoza et al. | |
| <input checked="" type="checkbox"/> | DY | US 2003/0187254 | 10/2/2003 | Perry, David A. et al. | |
| <input checked="" type="checkbox"/> | DZ | US 2003/0191112 | 10/9/2003 | Dorwald, Florencio Zaragoza et al. | |
| <input checked="" type="checkbox"/> | EA | US 2003/0195188 | 10/16/2003 | Boehringer, Markus et al. | |
| <input checked="" type="checkbox"/> | EB | US 2003/0195190 | 10/16/2003 | Peschke, Bernd et al. | |
| <input checked="" type="checkbox"/> | EC | US 2003/0199528 | 10/23/2003 | Kanstrup, Anders B. et al. | |
| <input checked="" type="checkbox"/> | ED | US 2003/0199563 | 10/23/2003 | Robl, Jeffrey A. et al. | |
| <input checked="" type="checkbox"/> | EE | US 2003/0203946 | 10/30/2003 | Behrens, Carsten et al. | |
| <input checked="" type="checkbox"/> | EF | US 2003/0216382 | 11/20/2003 | Boehringer, Markus et al. | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 14

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | |
|---|----|-----------------|------------|-----------------------------------|--|
| ✓ | EG | US 2003/0216450 | 11/20/2003 | Evans, David Michael et al. | |
| | EH | US 2003/0220345 | 11/27/2003 | Hamby, James Marino et al. | |
| | EI | US 2003/0225102 | 12/4/2003 | Sankaranarayanan, Alangudi | |
| | EJ | US 2003/0232761 | 12/18/2003 | Hinke, Simon A. et al. | |
| | EK | US 6,521,644 | 2/18/2003 | Broqua, Pierre | |
| | EL | US 6,528,486 | 3/4/2003 | Larsen, Bjarne Due et al. | |
| | EM | US 6,545,170 | 4/8/2003 | Pitzels, Barnett S et al. | |
| | EN | US 6,548,529 | 4/15/2003 | Robl, Jeffrey A. et al. | |
| | EO | US 6,555,519 | 4/29/2003 | Washburn, William N. | |
| | EP | US 6,555,521 | 4/29/2003 | Hermeling, Ronald Norbert et al. | |
| | EQ | US 6,559,188 | 5/6/2003 | Gatlin, Marjorie Regan et al. | |
| | ER | US 6,573,096 | 6/3/2003 | Chen, Wen-Tien | |
| | ES | US 6,573,287 | 6/3/2003 | Sulsky, Richard B. et al. | |
| | ET | US 6,586,198 | 7/1/2003 | Brown, Nancy J. | |
| | EU | US 6,608,038 | 8/19/2003 | Caplan, Shari L. et al. | |
| | EV | US 6,617,340 | 9/9/2003 | Vilhauer, Edwin Bernard | |
| | EW | US 6,620,821 | 9/16/2003 | Robl, Jeffrey A. | |
| | EX | US 6,627,636 | 9/30/2003 | Robl, Jeffrey A. | |
| | EY | US 6,645,995 | 11/11/2003 | Kanstrup, Anders et al. | |
| | EZ | US2004/0002495 | 1/1/2004 | Sher, Philip et al. | |
| | FA | US2004/0002609 | 1/1/2004 | Hulin, Bernard | |
| | FB | US2004/0006062 | 1/8/2004 | Smallheer, Joanne M. et al. | |
| | FC | US2004/0009972 | 1/15/2004 | Ding, Charles Z. et al. | |
| | FD | US2004/0009998 | 1/15/2004 | Dhar, T. G. Murali et al. | |
| | FE | US2004/0034014 | 2/19/2004 | Kanstrup, Anders Bendtz et al. | |
| | FF | US2004/0053369 | 3/18/2004 | Abbott, Catherine Anne et al. | |
| | FG | US2004/0063935 | 4/1/2004 | Yasuda, Kosuke | |
| | FH | US2004/0072874 | 4/15/2004 | Sato, Nagaaki et al. | |
| | FI | US2004/0072892 | 4/15/2004 | Fukushima, Hiroshi et al. | |
| | FJ | US2004/0077645 | 4/22/2004 | Himmelsbach, Frank et al. | |
| | FK | US2004/0082497 | 4/29/2004 | Evans, David Michael et al. | |
| | FL | US2004/0082607 | 04/29/2004 | Oi, Satou et al. | |
| | FM | US2004/0087587 | 5/6/2004 | Himmelsbach, Frank et al. | |
| | FN | US2004/0092478 | 5/13/2004 | Rothermel, John D. et al. | |
| | FO | US2004/0097510 | 5/20/2004 | Himmelsbach, Frank et al. | |
| | FP | US2004/0106655 | 6/3/2004 | Kitajima, Hiroshi et al. | |
| | FQ | US2004/0106656 | 6/3/2004 | Ashton, Wallace T. et al. | |
| ✓ | FR | US2004/0106802 | 6/3/2004 | Sankaranarayanan, Alangudi et al. | |

Examiner
Signature

Date

Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **5** of **14****Complete if Known**

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | |
|---|----|----------------|------------|------------------------------------|--|
| ✓ | FS | US2004/0110817 | 6/10/2004 | Hulin, Bernard | |
| | FT | US2004/0116328 | 6/17/2004 | Yoshikawa, Seiji et al. | |
| | FU | US2004/0132713 | 7/8/2004 | Hulin, Bernard et al. | |
| | FV | US2004/0138148 | 7/15/2004 | Fushimi, Nobuhiko et al. | |
| | FW | US2004/0138214 | 7/15/2004 | Himmelsbach, Frank et al. | |
| | FX | US2004/0138215 | 7/15/2004 | Eckhardt, Matthias et al. | |
| | FY | US2004/0147434 | 7/29/2004 | Ansorge, Siegfried et al. | |
| | FZ | US2004/0152192 | 8/5/2004 | Bachovchin, William et al. | |
| | GA | US2004/0152745 | 8/5/2004 | Jackson, Paul et al. | |
| | GB | US2004/0166125 | 8/26/2004 | Himmelsbach, Frank et al. | |
| | GC | US2004/0167133 | 8/26/2004 | Edmondson, Scott D. et al. | |
| | GD | US2004/0167341 | 8/26/2004 | Haffner, Curt Dale et al. | |
| | GE | US2004/0171104 | 9/2/2004 | Blinkovsky, Alexander et al. | |
| | GF | US2004/0171848 | 9/2/2004 | Haffner, Curt Dale et al. | |
| | GG | US2004/0176406 | 9/9/2004 | Gobbi, Luca Claudio et al. | |
| | GH | US2004/0176428 | 9/9/2004 | Edmondson, Scott D et al. | |
| | GI | US2004/0180925 | 9/16/2004 | Matsuno, Kenji et al. | |
| | GJ | US2004/0186153 | 9/23/2004 | Yasuda, Nobuyuki et al. | |
| | GK | US2004/0198786 | 10/7/2004 | Gretzke, Dirk et al. | |
| | GL | US2004/0209891 | 10/21/2004 | Broqua, Pierre et al. | |
| | GM | US2004/0229820 | 11/18/2004 | Bachovchin, William W. et al. | |
| | GN | US2004/0229848 | 11/18/2004 | Demuth, Hans-Ulrich et al. | |
| | GO | US2004/0236102 | 11/25/2004 | Brockunier, Linda et al. | |
| | GP | US2004/0242566 | 12/2/2004 | Feng, Jun et al. | |
| | GQ | US2004/0242568 | 12/2/2004 | Feng, Jun et al. | |
| | GR | US2004/0242636 | 12/2/2004 | Haffner, Curt Dale et al. | |
| | GS | US2004/0242898 | 12/2/2004 | Hulin, Bernard et al. | |
| | GT | US2004/0254167 | 12/16/2004 | Biftu, Tesfaye et al. | |
| | GU | US2004/0254226 | 12/16/2004 | Feng, Jun et al. | |
| | GV | US2004/0259843 | 12/23/2004 | Madar, David J. et al. | |
| | GW | US2004/0259870 | 12/23/2004 | Feng, Jun et al. | |
| | GX | US2004/0259883 | 12/23/2004 | Sakashita, Hiroshi et al. | |
| | GY | US2004/0259902 | 12/23/2004 | Boehringer, Markus et al. | |
| | GZ | US2004/0259903 | 12/23/2004 | Boehringer, Markus et al. | |
| | HA | US2004/0259919 | 12/23/2004 | Magnin, David R. et al. | |
| | HB | US 6,673,815 | 1/6/2004 | Devasthale, Pratik et al. | |
| | HC | US 6,673,829 | 1/6/2004 | Dorwald, Florencio Zaragoza et al. | |
| ✓ | HD | US 6,686,337 | 2/3/2004 | Connor, Gregory S. | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 14

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | |
|----|----|----------------|------------|-------------------------------|--|
| KH | HE | US 6,699,871 | 3/2/2004 | Edmondson, Scott D. et al. | |
| | HF | US 6,706,742 | 3/16/2004 | De Nanteuil, Guillaume et al. | |
| | HG | US 6,710,040 | 3/23/2004 | Hulin, Bernard et al. | |
| | HH | US 6,716,843 | 4/6/2004 | De Nanteuil, Guillaume et al. | |
| | HI | US 6,727,261 | 4/27/2004 | Gobbi, Luca Claudio et al. | |
| | HJ | US 6,727,271 | 4/27/2004 | Cheng, Peter T. et al. | |
| | HK | US 6,800,650 | 10/5/2004 | Boehringer, Markus et al. | |
| | HL | US 6,803,357 | 10/12/2004 | Bachovchin, William A. et al. | |
| | HM | US 6,825,169 | 11/30/2004 | Bachovchin, William W. et al. | |
| | HN | US2005/0014732 | 1/20/2005 | Gulve, Eric Arthur et al. | |
| | HO | US2005/0014946 | 1/20/2005 | Demuth, Hans-Ulrich et al. | |
| | HP | US2005/0020574 | 1/27/2005 | Hauel, Norbert et al. | |
| | HQ | US2005/0026921 | 2/3/2005 | Eckhardt, Matthias et al. | |
| | HR | US2005/0032804 | 2/10/2005 | Cypes, Stephen Howard et al. | |
| | HS | US2005/0038020 | 2/17/2005 | Hamann, Lawrence G. et al. | |
| | HT | US2005/0043292 | 2/24/2005 | Parker, Janice C. et al. | |
| | HU | US2005/0043299 | 2/24/2005 | Evans, David M. et al. | |
| | HV | US2005/0058635 | 3/17/2005 | Demuth, Hans-Ulrich et al. | |
| | HW | US 6,861,440 | 3/1/2005 | Boehringer, Markus et al. | |
| | HX | US 6,867,205 | 3/15/2005 | Boehringer, Markus et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|-----------------------|----|---|-----------------------------------|---|--|----------------|
| | | Country Code ² - Number ⁴ - Kind Code ⁶ (if known) | | | | |
| KH | HY | DE 2361551A1 | 6/19/1975 | BASF AG | | |
| | HZ | DE 2500024A1 | 7/8/1976 | BASF AG, | | |
| | IA | EP 0505893 | 9/30/1992 | MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG | | |
| | IB | EP 0547514 | 6/23/1993 | MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG | | |
| | IC | EP 0574846 | 12/22/1993 | MERCK PATENT GmbH | | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

14

Complete if Known

Application Number

10/809,638

Filing Date

March 24, 2004

First Named Inventor

Jun FENG

Group Art Unit

1614

Examiner Name

Not Yet Assigned

Attorney Docket Number

DPP-IV-5004-C3

| | | | | | | |
|-----|----|-------------|------------|---|--|--|
| 141 | ID | EP 0657452 | 6/14/1995 | MERCK PATENT GmbH | | |
| | IE | EP 0702013 | 3/20/1996 | MERCK PATENT GmbH | | |
| | IF | GB 1441665A | 7/7/1976 | COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION | | |
| | IG | WO 91/11457 | 8/8/1991 | BUCKLEY, Douglas, I. Et al. | | |
| | IH | WO 95/15309 | 6/8/1995 | FERRING B.V. | | |
| | II | WO 95/29691 | 11/9/1995 | GEORGIA TECH RESEARCH CORPORATION | | |
| | IJ | WO 96/02667 | 2/1/1996 | AMGEN INC. | | |
| | IK | WO 98/18763 | 5/7/1998 | TANABE SEIYAKU CO., LTD. | | |
| | IL | WO 98/19998 | 5/14/1998 | NOVARTIS AG | | |
| | IM | WO 98/50046 | 11/12/1998 | TRUSTEES OF TUFTS COLLEGE | | |
| | IN | WO 98/51803 | 11/19/1998 | NOVO NORDISK BIOTECH, INC. | | |
| | IO | WO 99/02705 | 1/21/1999 | SOCIETE DES PRODUITS NESTLE S.A. | | |
| | IP | WO 99/17799 | 4/15/1999 | TRUSTEES OF TUFTS COLLEGE ET AL. | | |
| | IQ | WO 99/18856 | 4/22/1999 | CYTOVIA, INC. | | |
| | IR | WO 99/28474 | 6/10/1999 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES | | |
| | IS | WO 99/46272 | 9/16/1999 | FONDATECH BENELUX N.V. | | |
| | IT | WO 99/47152 | 9/23/1999 | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | | |
| | IU | WO 99/62914 | 12/9/1999 | POINT THERAPEUTICS, INC. | | |
| | IV | WO 00/10549 | 3/2/2000 | POINT THERAPEUTICS, INC. | | |
| | IW | WO 00/20416 | 4/13/2000 | GANTE, Helga | | |
| | IX | WO 00/40583 | 7/13/2000 | MERCK PATENT GMBH | | |
| | IY | WO 00/43366 | 7/27/2000 | KIRIN BEER KABUSHIKI KAISHA | | |
| | IZ | WO 00/56296 | 9/28/2000 | FERRING BV | | |
| | JA | WO 00/56297 | 9/28/2000 | FERRING B.V. | | |
| | JB | WO 01/16301 | 3/8/2001 | TUFTS UNIVERSITY | | |

Examiner
Signature*[Handwritten Signature]*Date
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

14

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | | |
|----|----|--------------|------------|---|--|--|
| K1 | JC | WO 01/19866 | 3/22/2001 | THE UNIVERSITY OF SYDNEY | | |
| | JD | WO 01/40180 | 6/7/2001 | FERRING BV | | |
| | JE | WO 01/55105 | 8/2/2001 | NOVO NORDISK A/S | | |
| | JF | WO 01/62266 | 8/30/2001 | NOVO NORDISK A/S | | |
| | JG | WO 01/68603 | 9/20/2001 | BRISTOL-MYERS SQUIBB CO. | | |
| | JH | WO 01/72290 | 10/4/2001 | PROBIODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH | | |
| | JI | WO 01/74299 | 10/11/2001 | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | | |
| | JJ | WO 01/79206 | 10/25/2001 | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | | |
| | JK | WO 01/81304 | 11/1/2001 | FERRING BV | | |
| | JL | WO 01/81337 | 11/1/2001 | FERRING B.V. | | |
| | JM | WO 01/89569 | 11/29/2001 | INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH IMTM | | |
| | JN | WO 01/94597 | 12/13/2001 | PROZYMEX A/S | | |
| | JO | WO 02/04610 | 1/17/2002 | BAYER AKTIENGESELLSCHAFT | | |
| | JP | WO 02/051836 | 7/4/2002 | KYOWA HAKKO KOGYO CO., LTD | | |
| | JQ | WO 02/053170 | 7/11/2002 | INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (MTM) | | |
| | JR | WO 02/059301 | 8/1/2002 | K.U. LEUVEN RESEARCH AND DEVELOPMENT | | |
| | JS | WO 02/059343 | 8/1/2002 | VANDERBILT UNIVERSITY | | |
| | JT | WO 02/062764 | 8/15/2002 | TAKEDA CHEMICAL INDUSTRIES, LTD. | | |
| | JU | WO 02/066627 | 8/29/2002 | BAYER AKTIENGESELLSCHAFT | | |
| | JV | WO 02/068420 | 9/6/2002 | BOEHRINGER INGELHEIM PHARMA KG | | |
| | JW | WO 02/076450 | 10/3/2002 | MERCK & CO., INC. | | |
| | JX | WO 02/083128 | 10/24/2002 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | JY | WO 02/08931 | 1/31/2002 | TEN SQUARE | | |
| | JZ | WO 02/092127 | 11/21/2002 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | | |
| | KA | WO 02/096357 | 12/5/2002 | BRISTOL-MYERS SQUIBB COMPANY | | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| Sheet 9 of 14 | Attorney Docket Number | DPP-IV-5004-C3 | |

| | | | | | | |
|----|----|--------------|-----------|--|--|--|
| KN | KB | WO 02/14271 | 2/21/2002 | WELFIDE CORPORATION | | |
| | KC | WO 02/20804 | 3/14/2002 | PROZYMEX A/S | | |
| | KD | WO 02/26703 | 4/4/2002 | PROLIFIX LIMITED | | |
| | KE | WO 02/28742 | 4/11/2002 | JOHANSSON, Thomas | | |
| | KF | WO 02/30890 | 4/18/2002 | TANABE SEIYAKU CO., LTD. | | |
| | KG | WO 02/30891 | 4/18/2002 | TANABE SEIYAKU CO., LTD. | | |
| | KH | WO 02/31134 | 4/18/2002 | FERRING BV | | |
| | KI | WO 02/34900 | 5/2/2002 | THE UNIVERSITY OF SYDNEY | | |
| | KJ | WO 02/38541 | 5/16/2002 | TAISHO PHARMACEUTICAL CO., LTD. | | |
| | KK | WO 02/38742 | 5/16/2002 | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | | |
| | KL | WO 03/000180 | 1/3/2003 | MERCK & CO., INC. | | |
| | KM | WO 03/000250 | 1/3/2003 | FERRING BV | | |
| | KN | WO 03/002530 | 1/9/2003 | SMITHKLINE BEECHAM CORPORATION | | |
| | KO | WO 03/002531 | 1/9/2003 | SMITHKLINE BEECHAM CORPORATION | | |
| | KP | WO 03/002553 | 1/9/2003 | SMITHKLINE BEECHAM CORPORATION | | |
| | KQ | WO 03/004496 | 1/16/2003 | NOVO NORDISK A/S | | |
| | KR | WO 03/004498 | 1/16/2003 | MERCK & CO., INC. | | |
| | KS | WO 03/010197 | 2/6/2003 | GENSET S.A. | | |
| | KT | WO 03/010314 | 2/6/2003 | GENSET S.A. | | |
| | KU | WO 03/011807 | 2/13/2003 | NOVO NORDISK A/S | | |
| | KV | WO 03/011814 | 2/13/2003 | NOVO NORDISK A/S | | |
| | KW | WO 03/011834 | 2/13/2003 | NOVO NORDISK A/S | | |
| | KX | WO 03/011892 | 2/13/2003 | THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | | |
| | KY | WO 03/014318 | 2/20/2003 | GENZYME CORPORATION | | |
| | KZ | WO 03/015775 | 2/27/2003 | PROBIODRUG AG | | |
| | LA | WO 03/017936 | 3/6/2003 | YALE UNIVERSITY | | |
| | LB | WO 03/024942 | 3/27/2003 | MITSUBISHI PHARMA CORPORATION | | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 14

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/809,638 |
| Filing Date | March 24, 2004 |
| First Named Inventor | Jun FENG |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | DPP-IV-5004-C3 |

| | | | | | | |
|----|----|--------------|------------|--|--|--|
| KM | LC | WO 03/024965 | 3/27/2003 | NOVO NORDISK A/S | | |
| | LD | WO 03/035067 | 5/1/2003 | FERRING B.V. | | |
| | LE | WO 03/037327 | 5/8/2003 | F. HOFFMANN-LA-ROCHE AG | | |
| | LF | WO 03/038123 | 5/8/2003 | NOVARTIS AG | | |
| | LG | WO 03/040114 | 5/15/2003 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | LH | WO 03/051848 | 6/26/2003 | FERRING BV | | |
| | LI | WO 03/053330 | 3/7/2003 | ASTRAZENECA AB | | |
| | LJ | WO 03/055881 | 7/10/2003 | F. HOFFMANN-LA ROCHE AG | | |
| | LK | WO 03/057144 | 7/17/2003 | GUILFORD PHARMACEUTICALS | | |
| | LL | WO 03/057666 | 7/17/2003 | GUILFORD PHARMACEUTICALS | | |
| | LM | WO 03/065983 | 8/14/2003 | MERCK & CO., INC. | | |
| | LN | WO 03/068748 | 8/21/2003 | F. HOFFMANN-LA ROCHE AG | | |
| | LO | WO 03/068757 | 8/21/2003 | F. HOFFMANN-LA ROCHE AG | | |
| | LP | WO 03/072197 | 9/4/2003 | PFIZER PRODUCTS INC. | | |
| | LQ | WO 03/074500 | 9/12/2003 | SANOFI-SYNTHELABO | | |
| | LR | WO 03/076393 | 9/18/2003 | NOVARTIS AG | | |
| | LS | WO 03/077935 | 9/25/2003 | IMTM INSTITUT FUR MEDIZINTECHNOLOGIE MAGDEBURG GMBH, | | |
| | LT | WO 03/080070 | 10/2/2003 | NOVARTIS AG | | |
| | LU | WO 03/080633 | 10/2/2003 | NIPPON KAYAKU KABUSHIKI KAISHA | | |
| | LV | WO 03/082817 | 10/9/2003 | MERCK & CO., INC. | | |
| | LW | WO 03/082859 | 10/9/2003 | NOVARTIS AG | | |
| | LX | WO 03/084940 | 10/16/2003 | SANKARANARAYANAN, Alangudi | | |
| | LY | WO 03/101449 | 12/11/2003 | PFIZER PRODUCTS INC. | | |
| | LZ | WO 03/101958 | 12/11/2003 | PFIZER PRODUCTS INC. | | |
| | MA | WO 03/104207 | 12/18/2003 | MERCK & CO., INC. | | |
| | MB | WO 03/104208 | 12/18/2003 | MERCK & CO., INC. | | |
| | MC | WO 03/104229 | 12/18/2003 | EISAI CO., LTD. | | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

11

of

14

Complete if Known

Application Number

10/809,638

Filing Date

March 24, 2004

First Named Inventor

Jun FENG

Group Art Unit

1614

Examiner Name

Not Yet Assigned

Attorney Docket Number

DPP-IV-5004-C3

| | | | | | | |
|----|----|--------------|------------|---|--|--|
| KK | MD | WO 03/106456 | 12/24/2003 | SANOFI-SYNTHELABO | | |
| | ME | WO 04/002535 | 1/8/2004 | HORMOS MEDICAL CORPORATION | | |
| | MF | WO 04/002986 | 1/8/2004 | BANYU PHARMACEUTICAL CO., LTD. | | |
| | MG | WO 04/004655 | 1/15/2004 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | MH | WO 04/004661 | 1/15/2004 | POINT THERAPEUTICS, INC. | | |
| | MI | WO 04/004665 | 1/15/2004 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | MJ | WO 04/007446 | 1/22/2004 | YAMANOUCHI PHARMACEUTICAL CO., LTD. | | |
| | MK | WO 04/007468 | 1/22/2004 | MERCK & CO., INC. | | |
| | ML | WO 04/011640 | 2/5/2004 | TANABE SEIYAKU CO., LTD. | | |
| | MM | WO 04/014860 | 2/19/2004 | TAKEDA CHEMICAL INDUSTRIES, LTD. | | |
| | MN | WO 04/018467 | 3/4/2004 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | | |
| | MO | WO 04/018468 | 3/4/2004 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | | |
| | MP | WO 04/018469 | 3/4/2004 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | | |
| | MQ | WO 04/020407 | 3/11/2004 | TAISHO PHARMACEUTICAL CO., LTD. | | |
| | MR | WO 04/024184 | 3/25/2004 | TAKEDA CHEMICAL INDUSTRIES, LTD. | | |
| | MS | WO 04/026822 | 4/1/2004 | ABBOTT LABORATORIES | | |
| | MT | WO 04/028524 | 4/8/2004 | EISAI CO., LTD. | | |
| | MU | WO 04/031175 | 4/15/2004 | BANYU PHARMACEUTICAL CO., LTD. | | |
| | MV | WO 04/032836 | 4/22/2004 | MERCK & CO., INC. | | |
| | MW | WO 04/032861 | 4/22/2004 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | MX | WO 04/033455 | 4/22/2004 | NOVO NORDISK A/S | | |
| | MY | WO 04/037169 | 5/6/2004 | MERCK & CO., INC. | | |
| | MZ | WO 04/037181 | 5/6/2004 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | NA | WO 04/041795 | 5/21/2004 | GUILFORD PHARMACEUTICALS INC. | | |
| | NB | WO 04/043940 | 5/27/2004 | MERCK & CO., INC. | | |
| | NC | WO 04/046106 | 6/3/2004 | PFIZER PRODUCTS INC., | | |

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | DPP-IV-5004-C3 |
| Sheet | 12 | of | 14 |

| | | | | | | |
|----|----|--------------|------------|---|--|--|
| KH | ND | WO 04/048352 | 6/10/2004 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | NE | WO 04/050022 | 6/17/2004 | MERCK & CO., INC. | | |
| | NF | WO 04/050656 | 6/17/2004 | EISAI CO., LTD. | | |
| | NG | WO 04/050658 | 6/17/2004 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | | |
| | NH | WO 04/052850 | 8/24/2004 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | NI | WO 04/058266 | 7/15/2004 | MERCK & CO., INC. | | |
| | NJ | WO 04/064778 | 8/5/2004 | MERCK & CO. INC. | | |
| | NK | WO 04/067509 | 8/12/2004 | SANWA KAGAKU KENKYUSHO CO., LTD. | | |
| | NL | WO 04/069162 | 8/19/2004 | MERCK & CO., INC. | | |
| | NM | WO 04/071454 | 8/26/2004 | GUILFORD PHARMACEUTICALS INC. | | |
| | NN | WO 04/075815 | 9/10/2004 | AVENTIS PHARMA DEUTSCHLAND GMBH | | |
| | NO | WO 04/075891 | 9/10/2004 | AVENTIS PHARMA DEUTSCHLAND GMBH | | |
| | NP | WO 04/076401 | 9/10/2004 | AVENTIS PHARMA DEUTSCHLAND GMBH | | |
| | NQ | WO 04/076433 | 9/10/2004 | AIC | | |
| | NR | WO 04/076434 | 9/10/2004 | AIC | | |
| | NS | WO 04/078777 | 9/16/2004 | BIOREXIS PHARMACEUTICAL CORPORATION | | |
| | NT | WO 04/080958 | 9/23/2004 | MERCK & CO. INC. | | |
| | NU | WO 04/083212 | 9/30/2004 | MERCK & CO., INC. | | |
| | NV | WO 04/085661 | 10/7/2004 | MERCK & CO., INC. | | |
| | NW | WO 04/087053 | 10/14/2004 | SYRRX, INC. | | |
| | NX | WO 04/087650 | 10/14/2004 | MERCK & CO. INC. | | |
| | NY | WO 04/087880 | 10/14/2004 | BAYER PHARMACEUTICALS CORPORATION | | |
| | NZ | WO 04/089382 | 10/21/2004 | NOVO NORDISK A/S | | |
| | OA | WO 04/096806 | 11/11/2004 | SUMITOMO PHARMACEUTICALS CO. LTD. | | |
| | OB | WO 04/098825 | 11/18/2004 | PROBIODRUG AG | | |
| | OC | WO 04/099134 | 11/18/2004 | PROSIDION LTD. | | |
| | OD | WO 04/099185 | 11/18/2004 | FUJISAWA PHARMACEUTICAL CO. LTD. | | |
| | OE | WO 04/101514 | 11/25/2004 | TAISHO PHARMACEUTICAL CO., LTD. | | |
| | OF | WO 04/103276 | 12/2/2004 | MERCK & CO., INC. | | |
| | OG | WO 04/103993 | 12/2/2004 | SYRRX, INC. | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| Sheet 13 of 14 | Attorney Docket Number | DPP-IV-5004-C3 | |

| | | | | | | |
|----|----|----------------|------------|---|--|--|
| KH | OH | WO 04/110436 | 12/23/2004 | MERCK & CO., INC. | | |
| | OI | WO 04/111041 | 12/23/2004 | FUJISAWA PHARMACEUTICAL CO., LTD. | | |
| | OJ | WO 04/111051 | 12/23/2004 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | | |
| | OK | WO 04/112701 | 12/29/2004 | MERCK & CO., INC. | | |
| | OL | WO 05/000846 | 1/8/2005 | F.HOFFMANN-LA ROCHE AG | | |
| | OM | WO 05/003135 | 1/13/2005 | MERCK & CO., INC. | | |
| | ON | WO 05/011581 | 2/10/2005 | MERCK & CO., INC. | | |
| | OO | WO 05/012249 | 2/10/2005 | BRISTOL-MYERS SQUIBB COMPANY | | |
| | OP | WO 05/019168 | 3/3/2005 | PFIZER PRODUCTS INC. | | |
| | OQ | WO 2005/016911 | 2/24/2005 | Symx, Inc. | | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | |
| KH | OR | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCL.CHEM., Vol. 305, 1972, pages 724-730. | |
| | OS | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J.ORG.CHEM., Vol. 43, 1978, pages 4069-4074. | |
| | OT | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 386682 & J.CHEM.SOC., 1952, pages 4985-4990. | |
| | OU | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389575 & CHEM.BER., Vol. 88, 1968, pages 106-109. | |
| | OV | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 106-109. | |
| | OW | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689. | |
| | OX | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448669 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689. | |
| | OY | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J.CHEM.SOC.PERKIN TRANS.1, 1980, pages 1370-1380. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1614 |
| | | Examiner Name | Not Yet Assigned |
| Sheet 14 of 14 | Attorney Docket Number | DPP-IV-5004-C3 | |

| | | | |
|----|----|--|--|
| KH | OZ | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1166-1168. | |
| | PA | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6219070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324. | |
| | PB | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392446, J.HETEROCYCL.CHEM., Vol. 8, 1971, pages 367-371. | |
| | PC | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J. PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151. | |
| | PD | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185. | |
| | PE | Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335063. Database Accession no. 1525341 & J. HETEROCYCL.CHEM., Vol. 12, 1975, pages 683-687. | |
| | PF | GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-636, XP000889664 compound 1 | |
| | PG | Kesarwani, A. P. et al.: Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581. | |
| | PH | Rauchman, B.S. et al. "2,4-Diamino-5-benzylpyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP002335048 Scheme II | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/19/2006 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | |
|------------------------|--------------|
| Application Number | 10809638 |
| Filing Date | 2004-03-24 |
| First Named Inventor | Jun FENG |
| Art Unit | 1624 |
| Examiner Name | Kahsay Habte |
| Attorney Docket Number | DPP4-5004-C3 |

U.S. PATENTS

[Remove](#)

| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|--------------------------|
| KU | 1 | EP 900568 A2 | EP | | 1999-10-03 | Chenard et al. | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|----------------|
| | | | |

Handwritten signature

10/19/2006


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|--------------|------------|
| Application Number | | 10809638 |
| Filing Date | | 2004-03-24 |
| First Named Inventor | Jun FENG | |
| Art Unit | 1624 | |
| Examiner Name | Kahsay Habte | |
| Attorney Docket Number | DPP4-5004-C3 | |

| | | | |
|----|---|--|--------------------------|
| KN | 1 | Chenard et al. J. Med Chem. 2001, 44, 1710-1717 | <input type="checkbox"/> |
| I | 2 | An abstract of Pattanaik et al. Indian Journal of Chemistry, Section B; Organic Chemistry including Medicinal Chemistry (1998), 37B (12), 1304-1306 from STN CAS online search printout (3 pages). | <input type="checkbox"/> |
| I | 3 | Abstract of EP 900568 A2 from STN CAS online search printout (3 pages). | <input type="checkbox"/> |
| I | 4 | Kozhevnikov et al. Tr. Perm. Sel.-Khoz. Inst. (1971), No. 79, 66-72 From ref. Zh., Khim. 1972, Abstr. No. 9Zh404 Journal (English Abstract attached). | <input type="checkbox"/> |
| ↓ | 5 | Somasekhara et al. Indian Journal of Pharmacey (1972), 34(5), 121-2. | <input type="checkbox"/> |


If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Kahsay Habte |
| Sheet 1 of 2 | Attorney Docket Number | DPP4-5004-C3 | |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|---|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date/ Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| KH | AA | US 3,544,570 | 12-1-1970 | Helmut Timmler et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| KH | AB | GB 1464248 A | 02-09-1977 | Imperial Chem Ind Ltd | | |
| | AC | DE 2801289 A1 | 05-03-1979 | Hoechst AG | | |
| | AD | WO 02/09718 A | 02-07-2002 | The Procter & Gamble Company | | |
| | AE | WO 03/099286 | 12-04-2003 | Bristol-Myers Squibb Co. | | |
| | AF | DE 10256264 A | 08-24-2004 | Boehringer Ingelheim Pharma GMBH & Co. Kg | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| KH | AG | Dumas, Donald J. "Total synthesis of peramine" Journal of Organic Chemistry, American Chemical Society, Easton, US, Vol. 5, 1988, pages 4650-4653, XP002087391. | |
| | AH | Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US; 1991, Bahaji E-H et al.: "Studies on Immunostimulating Derivatives Synthesis of Some Pyrrolo-1 2-C-Pyrimidines" XP002392081. Database accession no. PREV199192140000 abstract. | |
| | AI | Database Beilstein [online] Beilstein Crossfire Institut Zur Forderung Der Chemischen Wissenschaften, DE; 1991, XP002392082. Database Accession No. BRN 5340228 abstract. | |
| | AJ | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; Citation No. 5593878 1991, XP00239083. | |
| | AK | Database CA [online] Chemical Abstract service, Columbus, Ohio, US; Reg No 102482-94-0 Liu, Gang: "Fungal endophyte-epichloe and its secondary metabolites" XP002392084. Database Accession No. 2004:340837 abstract. | |

| | | | |
|-----------------------|--|--------------------|------------|
| Examiner Signature | | Date Considered | 10/19/2006 |
|-----------------------|--|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|----------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/809,638 |
| | | Filing Date | March 24, 2004 |
| | | First Named Inventor | Jun FENG |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Kahsay Habte |
| | | Attorney Docket Number | DPP4-5004-C3 |
| Sheet | 2 | of | 2 |

| | | | |
|----|----|--|--|
| KN | AL | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1924, XP002392085. Database Accession No. BRN 3799088 abstract. | |
| | AM | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1989 XP002392088. Database Accession No. BRN 5951213 abstract. | |
| | AN | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1960 XP002392087. Database Accession No. BRN 609897 abstract. | |
| | AO | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1993 XP002392088. Database Accession No. BRN 6139401 abstract. | |
| | AP | Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften DE; 1974 XP002392089. Database Accession No. BRN 514343 abstract. | |
| | AQ | Akahoshi, F. et al.: "Synthesis and pharmacological activity of triazolo[1,5-a]triazine derivatives inhibiting eosinophilia." Journal of Medicinal Chemistry, Vol. 41, no. 18, (1998-07-30), pages 2985-2993, XP002390903 | |
| | AR | Wang, F. et al.: "A novel Synthesis of Aryl[1,2-a]pyrazine Derivatives" Molecules, Molecular Diversity Preservation International, BASEL, CH, Vol. 9, May 2004 (2004-05), pages 574-582, XP002390904. | |
| | AS | Kotra, L. P. et al.: "4-Azido-2-pyrimidone Nucleosides and Related Chemistry" Journal of Organic Chemistry, American Chemical Society, Easton, US, Vol. 62, 1997, pages 7267-7271, XP002390905. | |
| | AT | Tam, S. Y-K, et al.: "Nucleosides 112. Synthesis of Some New Pyrazolo-1 5-A-1 3 5-Triazines and Their C Nucleosides" Journal of Organic Chemistry, Vol. 44, No. 25, 1979, pages 4547-4553, XP002390906. | |
| | AU | Molina, P. et al.: "Iminophosphorane-mediated annulation of 1,3,5-triazine to benzimidazole: Synthesis of 1,3,5-triazino[1,2-a]benzimidazoles" Synthesis 1992 Germany, No. 3, 1992- pages 297-302, XP002390907. | |
| | AV | Kobe, J. et al.: "The synthesis of s-triazolo[4.3-a]1,3,5-triazines" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 26, July 1970 (1970-07), pages 3357-3368, XP002390908. | |
| | AW | Buysens, K. J. et al.: "Synthesis of New Pyrrolo[3,4-b]- and [3,4-c]pyridin(on)es and related 1,7-Naphthyridinones and 2,7-naphthyridines via intramolecular diels-alder reactions of 2(1H)-pyrazinones" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 52, no. 27, (1996-07-01), pages 9161-9178, XP004104003. | |
| | AX | Abdel-Rahman, R. M.: "Synthesis of some new fluorine bearing trisubstituted 3-thioxo-1, 2, 4-triazin-5-ones as potential anticancer agents: Farmaco, Edizione Scientifica, Societa Chimica Italiana, Pavia, IT, Vol. 47, No. 3 (1992-03), pages 319-326, XP008000322. | |
| | AY | Borell, J. I. et al.: "Synthesis, structure and cytotoxicity evaluation of palladium(II) complexes of 4-amino-3-hydrazino-1,2,4-triazin-5(4H)-ones and 4-amino-3-(n-methylhydrazino)-1,2,4-triazin-5(4H)-ones" Analges De Quimica, Vol. 81, no. 3/4, 1995, pages 243-252, XP008000323. | |

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | |
|---|------------------------|--------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | 10809638 |
| | Filing Date | 2004-03-24 |
| | First Named Inventor | Jun Feng |
| | Art Unit | 1624 |
| | Examiner Name | Kahsay Hable |
| | Attorney Docket Number | DPP4-5004-C3 |

| U.S. PATENTS | | | | | | | Remove | |
|--|---------|---|-----------------------------|------------------------|---|--|--|--------------------------|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | |
| If you wish to add additional U.S. Patent citation information please click the Add button. | | | | | | | Add | |
| U.S. PATENT APPLICATION PUBLICATIONS | | | | | | | Remove | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | |
| If you wish to add additional U.S. Published Application citation information please click the Add button. | | | | | | | Add | |
| FOREIGN PATENT DOCUMENTS | | | | | | | Remove | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| KN | 1 | WO 01/23364 A1 | WO | | 2001-04-05 | MERCK PATENT GMBH | | <input type="checkbox"/> |
| If you wish to add additional Foreign Patent Document citation information please click the Add button | | | | | | | Add | |
| NON-PATENT LITERATURE DOCUMENTS | | | | | | | Remove | |
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | T ⁵ |

At my Pa

10/19/2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|--------------|
| Application Number | 10809638 |
| Filing Date | 2004-03-24 |
| First Named Inventor | Jun Feng |
| Art Unit | 1624 |
| Examiner Name | Kahsay Habte |
| Attorney Docket Number | DPP4-5004-C3 |

| | | | |
|----|---|--|--------------------------|
| KH | 1 | STN Printout, Barnickel et al. Abstract of WO 01/23364 A1. | <input type="checkbox"/> |
|----|---|--|--------------------------|

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|---|-----------------|------------|
| Examiner Signature |  | Date Considered | 10/19/2006 |
|--------------------|---|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.